About

Jacob Khurgin is a professor of electrical and computer engineering at Johns Hopkins University, known for his diverse research in optics, electronics, condensed matter physics, and telecommunications. His work primarily lies at the intersection of optics and solid-state electronics, focusing on topics such as the optics of semiconductor nanostructures, nonlinear optical devices, lasers, optical communications, microwave photonics, and condensed matter physics. His recent research involves mid-infrared optical frequency combs, metamaterials, optical refrigeration of solids, and phonon engineering for high-frequency transistors. Khurgin's research has led to numerous inventions spanning from small appliances like electric shavers and coffeemakers to advanced systems for laser communication and chemical detection. He has published roughly 40 patents and has been involved in consulting for major companies including Philips Electronics, IBM, AT&T, and Hewlett Packard. His work has been funded by prominent agencies such as DARPA, AFOSR, the Office of Naval Research, NSF, NASA, and STTR. He is a member of the American Physical Society Joint Council on Quantum Electronics, has served as a technical program committee member for over 60 academic conferences, and has held visiting professorships at institutions including Princeton, UCLA, Brown, ETH Zurich, and Ecole Normale Superieure in Paris. Khurgin is a Fellow of the American Physical Society and the Optical Society of America, and he serves as an associate editor for Optica. He has reviewed papers for numerous journals, published eight book chapters, 340 refereed journal papers, and authored a book titled “Slow Light – Science and Applications.” He earned his BS and MS in Optics from the Institute of Fine Mechanics and Optics in St. Petersburg, Russia, in 1977 and 1979, respectively, and obtained his PhD in Electro-Physics from New York University in 1987. He joined Johns Hopkins University in 1988 after working as a researcher at Philips Laboratories in New York.

Research topics

• Medicine
• Computer Science
• Engineering
• Database
• Surgery
• Internal medicine
• Biomedical engineering
• Structural engineering
• Mechanical engineering
• Pharmacology
• Medical emergency

Selected publications

• Medications Most Commonly Associated with Erectile Dysfunction: Evaluation of the Food and Drug Administration National Pharmacovigilance Database

  Sexual Medicine · 2022 · 24 citations

  Senior authorCorresponding
  • Medicine
  • Internal medicine
  • Database

  Abstract Background Erectile dysfunction (ED) is an adverse effect of many medications. Aim We used a national pharmacovigilance database to assess which medications had the highest reported frequency of ED. Methods The Food and Drug Administration Adverse Event Reporting System (FAERS) was queried to identify medications with the highest frequency of ED adverse event reports from 2010 to 2020. Phosphodiesterase-5 inhibitors and testosterone were excluded because these medications are often used as treatments for men with ED. The 20 medications with the highest frequency of ED were included in the disproportionality analysis. Outcomes Proportional Reporting Ratios (PRRs) and their 95% confidence intervals were calculated. Results The 20 medications accounted for 6,142 reports of ED. 5-α reductase inhibitors (5-ARIs) and neuropsychiatric medications accounted for 2,823 (46%) and 2,442 (40%) of these reports respectively. Seven medications showed significant levels of disproportionate reporting with finasteride and dutasteride having the highest PRRs: 110.03 (103.14–117.39) and 9.40 (7.83–11.05) respectively. The other medications are used in a wide variety of medical fields such as cardiology, dermatology, and immunology. Clinical Implications Physicians should be familiar with these medications and understand their respective mechanisms of action, so that they may counsel patients appropriately and improve their quality of life. Strengths and Limitations The strength of the study is its large sample size and that it captures pharmacologic trends on a national level. Quantitative and comparative “real-world” data is lacking for the most common medications associated with ED. The limitation is that the number of reported events does not establish causality and cannot be used to calculate ED incidence rates. Conclusion In a national pharmacovigilance database, 5-ARIs and neuropsychiatric medications had the highest reports of ED adverse effects. There were many other medications used in a variety of medical fields that were also associated with ED.

  DOI

• Ultrafast quantum photonics enabled by coupling plasmonic nanocavities to strongly radiative antennas

  Optica · 2020 · 85 citations

  • Optoelectronics
  • Physics
  • Optics

  Quantum emitters coupled to plasmonic nanostructures can act as exceptionally bright sources of single photons, operating at room temperature. Plasmonic mode volumes supported by these nanostructures can be several orders of magnitude smaller than the cubic wavelength, which leads to dramatically enhanced light–matter interactions and drastically increased photon production rates. However, when increasing the light localization further, these deeply subwavelength modes may in turn hinder the fast outcoupling of photons into free space. Plasmonic hybrid nanostructures combining a highly confined cavity mode and a larger antenna mode circumvent this issue. We establish the fundamental limits for quantum emission enhancement in such systems and find that the best performance is achieved when the cavity and antenna modes differ significantly in size. We experimentally support this idea by photomodifying a nanopatch antenna deterministically assembled around a nanodiamond known to contain a single nitrogen–vacancy (NV) center. As a result, the cavity mode shrinks, further shortening the NV fluorescence lifetime and increasing the single-photon brightness. Our analytical and numerical simulation results provide intuitive insight into the operation of these emitter–cavity–antenna systems and show that this approach could lead to single-photon sources with emission rates up to hundreds of THz and efficiencies close to unity.

  DOI

• 035 Inflatable Penile Prosthesis Adverse Events: Comparison of the Alternative Summary Report (ASR) and Manufacturer and User Facility Device Experience (MAUDE) Databases

  The Journal of Sexual Medicine · 2020 · 1 citations

  Senior authorCorresponding
  • Computer Science
  • Database
  • Medicine

  Approximately 25,000 inflatable penile prostheses (IPP) are implanted in the United States annually. IPP mechanical survival is reported as 92.1-97.5% at five years post-implantation. The U.S. Food and Drug Administration (FDA) ended its alternative summary report (ASR) program in June 2019, which was first established in 1997. Under the ASR program, medical device manufacturers were able to obtain exemptions precluding them from the public domain. Six million medical device reports are now accessible. The FDA’s Manufacturer and User Facility Device Experience Database (MAUDE) has been a voluntarily-reported database of medical device complications, available to the public since 1991. To compare the rates of IPP mechanical malfunction as reported in the ASR and MAUDE databases. The ASR and MAUDE databases were accessed for January 1, 2018 to December 31, 2018. Reports specific to IPP manufacturers (American Medical Systems [AMS] / Boston Scientific [BS] and Coloplast/Mentor) were identified, analyzed for multiple entries, and grouped. IPP complications were categorized as device-related or non-device-related. Medical literature search was conducted.

  DOI

• 119 Analysis of the Cost of Inflatable Penile Prosthesis for Self-Pay Patients

  The Journal of Sexual Medicine · 2020

  Senior authorCorresponding
  • Medicine
  • Surgery
  • Engineering

  In the current healthcare marketplace, patients are increasingly identifying themselves as consumers. Elective medical procedures, such as inflatable penile prosthesis (IPP) insertion, are especially subject to out-of-pocket cost considerations. Within this context, we sought to analyze trends in self-pay/cash costs for elective IPP insertion among prominent urological surgeons specializing in prosthetics. To examine the out-of-pocket cost for IPP insertion for self-pay patients nationally, including potential barriers in accessing price transparency, and to identify possible factors contributing to price variation. Publically available information from the Internet was used to contact the medical offices of 27 prominent urological surgeons specializing in prosthetics. A quote was requested for the total cost of a routine IPP insertion, including the physician fee, operating room/anesthesia fee, device cost, and related postoperative care. We noted whether the information was available, if there was difficulty obtaining the information, device manufacturer preferences, and medical practice characteristics.

  DOI

Frequent coauthors

• Ariel Schulman

  Maimonides Medical Center

  9 shared

• Daniel Rabinowitz

  Maimonides Medical Center

  7 shared

• Uzoma A. Anele

  University of Louisville

  6 shared

• Arthur L. Burnett

  Johns Hopkins University

  6 shared

• Trinity J. Bivalacqua

  University of Pennsylvania

  4 shared

• Kathy Lue

  Bloomberg (United States)

  4 shared

• Daniel Friedlander

  University of Connecticut

  4 shared

• Jeffrey Lee

  Fairfax Neonatal Associates

  4 shared

Awards & honors

• Fellow of the American Physical Society
• Fellow of the Optical Society of America

Similar researchers at Johns Hopkins University

• Richard Huganirh-210
• Steven L. Salzbergh-191
• Arturo Casadevallh-152
• Peter Campochiaroh-139
• Alan Yuilleh-134